Grufity logo
Grufity logo
ARDS

ARDS - Aridis Pharmaceuticals Inc Stock Price, Fair Value and News

00
Market Closed as of 15 Jun 2026, 04:00 pm ET

Price Targets

00

ARDS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARDS Price Action

ARDS RSI Chart

ARDS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARDS Valuation

Market Cap

0

Price/Earnings (Trailing)

0

Price/Sales (Trailing)

0

Price/Free Cashflow

0

ARDS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

00

ARDS Fundamentals

ARDS Revenue

ARDS Earnings

ARDS Profitability

Free Cashflow Yield

0%

ARDS Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20233.0M22.3M22.4M-
20222.3M3.0M2.9M3.1M
2021-1.2M1.4M1.5M
2020-1.0M1.0M1.0M
20193.5M3.4M2.4M1.0M
20181.3M1.8M2.3M2.8M
2017---860.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Aridis Pharmaceuticals Inc

ARDS
Aridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.
 CEO
 WEBSITEaridispharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES37

Aridis Pharmaceuticals Inc Frequently Asked Questions

ARDS is the stock ticker symbol of Aridis Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed May 27 2026, market cap of Aridis Pharmaceuticals Inc is 0. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Wed May 27 2026, ARDS's PE ratio (Price to Earnings) is 0 and Price to Sales (PS) ratio is 0. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARDS PE ratio will change depending on the future growth rate expectations of investors.